Premium
Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity
Author(s) -
Sangster Philippa,
Kalsi Vinay
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2008.07824.x
Subject(s) - overactive bladder , botulinum neurotoxin , medicine , botulinum toxin , health care , economics , surgery , alternative medicine , economic growth , chemistry , biochemistry , pathology , toxin
Health economic aspects are crucial in arguing the feasibility of setting up a new service using an unlicensed treatment. Overall, the costs of intradetrusor botulinum neurotoxin‐A treatment appear to be modest relative to the improvement in quality of life. However, in managing the overactive bladder, there is a need for a widely accepted definition of ‘clinical improvement’ or a common outcome measure to direct future clinical and health economic research.